FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula I, where W is COR2 or CR3R4OR5; X is absent or X is CO or CR3R4; Y is absent or Y is O; Z is absent or Z is CR3R4; R1 is selected from a group, consisting of unsubstituted C5-20alkyl, C6aryl substituted with 1-2 substitutes selected from acetoxy and chlorine, and fragment (a); R is H; each of R2, R3 and R4 is H; and R5 is H. Invention also relates to a compound where the compound is selected from a group of compounds presented in the formula, a pharmaceutical composition containing a compound of formula I or a compound selected from the group of compounds, and the use of a compound of formula I or a compound selected from a group of compounds in the manufacture of a medicament for the treatment of atopic dermatitis.
EFFECT: treatment of atopic dermatitis.
12 cl, 30 dwg, 11 tbl, 34 ex
Title | Year | Author | Number |
---|---|---|---|
CRYSTALLINE FORM OF THIOPHENE DERIVATIVE AND METHOD FOR OBTAINING THEREOF | 2022 |
|
RU2830948C1 |
METHOD OF PRODUCING CRYSTALLINE FORM OF HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR | 2020 |
|
RU2823673C1 |
SALT OF MONOCYCLIC DERIVATIVE OF PYRIDINE AND CRYSTAL THEREOF | 2015 |
|
RU2658821C1 |
CONTAINING DERIVATIVE WITH THREE CONDENSED RINGS, SALT OR CRYSTALLINE FORM AND PHARMACEUTICAL COMPOSITION BASED THEREON | 2020 |
|
RU2835105C1 |
HYDROXYPURINE COMPOUNDS AND USE THEREOF | 2016 |
|
RU2685417C1 |
PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYLMETHYL GROUP | 2015 |
|
RU2707953C2 |
SALTS AND CRYSTALLINE FORMS OF DIAZABENZOFLUORANTHENE COMPOUNDS | 2017 |
|
RU2762189C2 |
COMPOUND OF BRD4 INHIBITOR IN SOLID FORM, METHOD FOR ITS PRODUCTION AND APPLICATION | 2020 |
|
RU2793346C1 |
COMPOUNDS TARGETING TAU PROTEIN AND RELATED USE THEREOF | 2017 |
|
RU2805523C2 |
CRYSTALLINE FORM OF SMAC MIMETIC USED AS IAP INHIBITOR, AND METHOD FOR PRODUCTION THEREOF | 2020 |
|
RU2819398C2 |
Authors
Dates
2025-04-22—Published
2022-09-02—Filed